Upgrade to SI Premium - Free Trial

Merck (MRK) Reiterated at Neutral by Cantor Fitzgerald As '26 Catalysts Already Credited

April 8, 2026 7:59 AM
Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $120.00 price target on Merck (NYSE: MRK).The analyst commented, "Our ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments